Pharmacokinetics of recombinant human insulin-like growth factor-I in diabetic rats

Drug Metabolism and Disposition

Volumn 25, Issue 11, 1997, Pages 1324-1327

  Kimura, Toshikiro ^a   Higaki, Kazutaka ^b   Matsumoto, Yukihiro ^b   Fujimoto, Rika ^b   Kurosaki, Yuji ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN; STREPTOZOCIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; MALE; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT; STREPTOZOCIN DIABETES;

ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, GEL; DIABETES MELLITUS, EXPERIMENTAL; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 0343554634     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. R. E. Humbel: Insulin-like growth factors I and II. Eur. J. Biochem. 190, 445-462 (1990).
2. P. F. Backeljauw and L. E. Underwood: Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome. J. Clin. Endocrinol. Metab. 81, 3312-3317 (1996).
3. J. C. Carel, J. L. Chaussain, P. Chatelain, and M. O. Savage: Growth hormone insensitivity syndrome (Laron syndrome) : Main characteristics and effects of IGF-I treatment. Diabetes Metab. 22, 251-256 (1996).
4. E. R. Froesch, M. A. Hussain, C. Schmid, and J. Zapf: Insulin-like growth factor-I: Physiology, metabolic effects and clinical uses. Diabetes Metab. Rev. 12, 195-215 (1996).
5. J. D. Quin, B. M. Fisher, K. R. Paterson, A. Inoue, G. H. Beastall, and A. C. MacCuish: Acute response to recombinant insulin-like growth factor I in a patient with Mendenhall's syndrome. N. Engl. J. Med. 323, 1425-1426 (1990).
6. L. A. Morrow, M. B. O'Brien, D. E. Moller, J. S. Flier, and A. C. Moses: Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in type A syndrome of severe insulin resistance. J. Clin. Endocrinol. Metab. 79, 205-210 (1994).
7. D. B. Dunger: Insulin and insulin-like growth factors in diabetes mellitus. Arch. Dis. Child. 72, 469-477 (1995).
8. T. Kimura, Y. Kanzaki, Y. Matsumoto, M. Mandai, Y. Kurosaki, and T. Nakayama: Disposition of recombinant human insulin-like growth factor-I in normal and hypophysectomized rats. Biol. Pharm. Bull. 17, 310-315 (1994).
9. K. Suzuki K. Hashimoto, T. Asada, S. Nakanishi, H. Horiai, and M. Niwa: Measurement of IGF-I/somatomedin-C in plasma by radioimmunoassay (RIA). Study on RIA using antiserum and monoclonal antibody against recombinant IGF-I. Clin. Pharmacol. (Japan) 35, 853-858 (1987).
10. K. Yamaoka, Y. Tanigawara, T. Nakagawa, and T. Uno: A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-Dyn. 4, 879-885 (1981).
11. M. A. Bach, E. Chin, and C. A. Bondy: The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 79, 1040-1045 (1994).
12. P. G. Whittaker, M. O. Stewart, A. Taylor, R. J. S. Howell, T. Lind: Insulin-like growth factor 1 and its binding protein 1 during normal and diabetic pregnancies. Obstet. Gynecol. 76, 223-229 (1990).
13. N. L. Bodkin, R. Sportsman, R. D. DiMarchi, and B. C. Hansen: Insulin-like growth factor-I in non-insulin-dependent diabetic monkeys: Basal plasma concentrations and metabolic effects of exogenously administered biosynthetic hormone. Metabolism 40, 1131-1137 (1991).
14. J. F. Hofert, S. Goldstein, and L. S. Phillips: Glucocorticoid effects on IGF-1/soma-tomedin-C and somatomedin inhibitor in streptozotocin-diabetic rats. Metabolism 38, 594-600 (1989).
15. M. S. Lewitt, H. Saunders, and R. C. Baxter: Bioavailability of insulin-like growth factors (IGFs) in rats determined by the molecular distribution of human IGF-binding protein-3. Endocrinology 133, 1797-1802 (1993).
16. M. D. Graubert, S. Goldstein, and L. S. Phillips: Nutrition and somatomedin XXVII. Total and free IGF-I and IGF binding proteins in rats with streptozocin-induced diabetes. Diabetes 40, 959-965 (1991).
17. T. G. Unterman, J. J. Jentel, D. T. Oehler, R. G. Lacson, and J. F. Hofert: Effects of glucocorticoids on circulating levels and hepatic expression of insulin-like growth factor (IGF)-binding proteins and IGF-I in the adrenalectomized streptozotocin-diabetic rat. Endocrinology 133, 2531-2539 (1993).
18. R. C. Baxter, J. L. Martin: Radioimmunoassay of growth hormone-dependent insulin-like growth factor binding protein in human plasma. J. Clin. Invest. 78, 1504-1512 (1986).
19. A. Juul, K. Main, W. F. Blum, J. Lindholm, M. B. Ranke, and N. E. Skakkebak: The ratio between serum levels of insulin-like growth factor (IGF-I) and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin. Endocrinol. 41, 85-93 (1994).
20. R. C. Baxter: Biochemical characterization of insulin-like growth factor binding proteins. Acta Endocrinol. 124, 33-40 (1991).
21. M. Phillip, Y. Segeve, A. Zung, A. A. Kowarski, H. Werner, C. T. Roberts, Jr., D. LeRoith, J. Ladas, and S. E. Mulroney: The accumulation of IGF-I in kidneys of streptozotocin-diabetic adult rats is not associated with elevated plasma GH or IGF-I levels. Endocrine 3, 689-693 (1995).
22. M. Phillip, D. Landau, Y. Segev, O. Weiss, and I. Raz: Insulin-like growth factors (IGFs) and IGF-binding proteins in diabetic kjdney disease. Isr. J. Med. Sci. 31, 712-716 (1995).